Literature DB >> 8395791

Activity of topoisomerase inhibitors against Pneumocystis carinii in vitro and in an inoculated mouse model.

J A Fishman1, S F Queener, R S Roth, M S Bartlett.   

Abstract

Five topoisomerase II inhibitors (amsacrine [m-AMSA], two epipodophyllotoxins, and two quinolones) and the alkaloid camptothecin (a topoisomerase I inhibitor) were evaluated to assess their activities against Pneumocystis carinii. In vitro, both etoposide (VP-16) and teniposide (VM-26) at 1 microgram/ml suppressed P. carinii growth. Amsacrine was toxic to P. carinii and to the feeder cells in vitro. Camptothecin suppressed the growth of P. carinii in vitro only at 100 micrograms/ml. Studies in immunosuppressed mice demonstrated the efficacy of teniposide against P. carinii pneumonia, but successful administration of teniposide was schedule dependent with significant toxicity at therapeutic dosages.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8395791      PMCID: PMC188010          DOI: 10.1128/AAC.37.7.1543

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  22 in total

1.  Activity of lipid-soluble inhibitors of dihydrofolate reductase against Pneumocystis carinii in culture and in a rat model of infection.

Authors:  S F Queener; M S Bartlett; M A Jay; M M Durkin; J W Smith
Journal:  Antimicrob Agents Chemother       Date:  1987-09       Impact factor: 5.191

2.  Antimicrobial susceptibility of Pneumocystis carinii in culture.

Authors:  M S Bartlett; R Eichholtz; J W Smith
Journal:  Diagn Microbiol Infect Dis       Date:  1985-09       Impact factor: 2.803

Review 3.  Inhibitors of DNA topoisomerases.

Authors:  K Drlica; R J Franco
Journal:  Biochemistry       Date:  1988-04-05       Impact factor: 3.162

Review 4.  Pneumocystis carinii pneumonia: therapy and prophylaxis.

Authors:  J A Kovacs; H Masur
Journal:  J Infect Dis       Date:  1988-07       Impact factor: 5.226

5.  Dose-dependent pharmacokinetic study of pefloxacin, a new antibacterial agent, in humans.

Authors:  J Barre; G Houin; J P Tillement
Journal:  J Pharm Sci       Date:  1984-10       Impact factor: 3.534

6.  New rat model of Pneumocystis carinii infection.

Authors:  M S Bartlett; J A Fishman; S F Queener; M M Durkin; M A Jay; J W Smith
Journal:  J Clin Microbiol       Date:  1988-06       Impact factor: 5.948

7.  Trimethoprim-sulfamethoxazole or pentamidine for Pneumocystis carinii pneumonia in the acquired immunodeficiency syndrome. A prospective randomized trial.

Authors:  J M Wharton; D L Coleman; C B Wofsy; J M Luce; W Blumenfeld; W K Hadley; L Ingram-Drake; P A Volberding; P C Hopewell
Journal:  Ann Intern Med       Date:  1986-07       Impact factor: 25.391

8.  Nephrotoxicity and hyperkalemia in patients with acquired immunodeficiency syndrome treated with pentamidine.

Authors:  M Lachaal; R C Venuto
Journal:  Am J Med       Date:  1989-09       Impact factor: 4.965

9.  High-performance liquid chromatography measurement of antimicrobial concentrations in polymorphonuclear leukocytes.

Authors:  H Koga
Journal:  Antimicrob Agents Chemother       Date:  1987-12       Impact factor: 5.191

Review 10.  Fluoroquinolone antimicrobial agents.

Authors:  J S Wolfson; D C Hooper
Journal:  Clin Microbiol Rev       Date:  1989-10       Impact factor: 26.132

View more
  8 in total

Review 1.  Treatment of infection due to Pneumocystis carinii.

Authors:  J A Fishman
Journal:  Antimicrob Agents Chemother       Date:  1998-06       Impact factor: 5.191

Review 2.  Prevention of infection due to Pneumocystis carinii.

Authors:  J A Fishman
Journal:  Antimicrob Agents Chemother       Date:  1998-05       Impact factor: 5.191

3.  A cytotoxicity assay for evaluation of candidate anti-Pneumocystis carinii agents.

Authors:  M T Cushion; F Chen; N Kloepfer
Journal:  Antimicrob Agents Chemother       Date:  1997-02       Impact factor: 5.191

4.  Immunodeficient and immunosuppressed mice as models to test anti-Pneumocystis carinii drugs.

Authors:  P D Walzer; J Runck; P Steele; M White; M J Linke; C L Sidman
Journal:  Antimicrob Agents Chemother       Date:  1997-02       Impact factor: 5.191

Review 5.  Prevention of infection due to Pneumocystis spp. in human immunodeficiency virus-negative immunocompromised patients.

Authors:  Martin Rodriguez; Jay A Fishman
Journal:  Clin Microbiol Rev       Date:  2004-10       Impact factor: 26.132

6.  Identification of a class of sulfonamides highly active against dihydropteroate synthase form Toxoplasma gondii, Pneumocystis carinii, and Mycobacterium avium.

Authors:  L C Chio; L A Bolyard; M Nasr; S F Queener
Journal:  Antimicrob Agents Chemother       Date:  1996-03       Impact factor: 5.191

7.  Evaluation of potent inhibitors of dihydrofolate reductase in a culture model for growth of Pneumocystis carinii.

Authors:  M S Bartlett; M Shaw; P Navaran; J W Smith; S F Queener
Journal:  Antimicrob Agents Chemother       Date:  1995-11       Impact factor: 5.191

8.  Molecular characterization of recombinant Pneumocystis carinii topoisomerase I: differential interactions with human topoisomerase I poisons and pentamidine.

Authors:  Rukiyah T van Dross; Marilyn M Sanders
Journal:  Antimicrob Agents Chemother       Date:  2002-07       Impact factor: 5.191

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.